Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA® (talazoparib) in ...
The FDA today expanded the approval of Talzenna (talazoparib) plus Xtandi (enzalutamide) to men with metastatic prostate cancer that has not been treated with androgen pathway dru ...
(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has expanded approval of TALZENNA ® (talazoparib ...
Recent study links blood proteins to aggressive prostate cancer, identifying potential biomarkers for early risk prediction ...
Adding abiraterone to standard treatment provides a lasting survival benefit for men whose prostate cancer has already spread ...
DASL-HiCaP Trial Shows Darolutamide Improves Metastasis-Free Survival in Very High-Risk Prostate Cancer / DASL-HiCaP Trial, ...
University Hospitals research suggests the Decipher tumor score could help doctors personalize treatment decisions for men ...
Men with very high-risk prostate cancer had a significantly lower risk of metastasis when they received darolutamide (Nubeqa) in addition to androgen deprivation therapy (ADT) and radiation therapy ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Immunohistochemical staining was positive in 48% of the 50 prostate cancer specimens and 18% of the 50 benign controls, a ...
Darolutamide with ADT significantly prolongs rPFS in metastatic prostate cancer while preserving tolerability. Read more here ...
A systematic review and meta-analysis of eight studies found elevated serum TK1 in prostate cancer and an association with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results